Journals / Acıbadem Üniversitesi Sağlık Bilimleri Dergisi / 2016 / Cilt: 7 - Sayı: 3

MULTİPLE MYELOMLU YAŞLI HASTADA PLAZMASİTOMU TAKLİT EDEN MİDE ADENOKARSİNOMU

Gastric Adenocarcinoma Mimicking Plasmacytoma During the Course of Multiple Myeloma(MM) in a Geriatric Patient

Pages
178–181
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Secondary malignancy risk should be kept in mind during the follow-up of patients with MM

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Multiple myeloma is the neoplastic proliferation of monoclonal plasma cells, usually bone marrow originated.
📊
Key Findings & Data:It may cause various organ dysfunctions.
💡
Conclusion & Impact:Secondary malignancy risk should be kept in mind during the follow-up of patients with MM
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Multiple myeloma is the neoplastic proliferation of monoclonal plasma cells, usually bone marrow originated. It may cause various organ dysfunctions. It is not so rare to detect secondary malignancies associated with MM but this co-existence between MM and gastric cancer has been not very frequently reported. Secondary malignancy risk should be kept in mind during the follow-up of patients with MM

Özet

Multiple myeloma genellikle kemik iliği kökenli monoklonal plazma hücrelerinin neoplastik proliferasyonudur. Birçok organda fonksiyon bozukluklarına yol açabilir. Multiple myelomlu hastalarda ikincil kanserler nadir olmamakla birlikte mide kanseri ve multiple myelom birlikteliğine literatürde az rastlanılmaktadır. İkincil kanser riski multiple myelomlu hastaların izleminde akılda tutulmalıdır

🔖

Cite This Article

ELBİ, H., GÖRGÜN, M., GÖRGÜN, G., GÖKER, E., ALP, A. (2022). MULTİPLE MYELOMLU YAŞLI HASTADA PLAZMASİTOMU TAKLİT EDEN MİDE ADENOKARSİNOMU. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 7 - Sayı: 3, 178–181. https://ajindex.com/articles/427473

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Sirohi B, Powles R. Multiple Myeloma. Lancet, 2004; 363: 875-87.
  2. Smith A, Wisloff F, Samson D, UK Myeloma Forum, Nordic Myeloma Study Group, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol, 2006; 132: 410-51.
  3. Dong C, Hemminki K. Second primary neoplasms among 53159 haematolymphoproliferative malignancy patients in Sweden, 1958- 1996: a search for common mechanisms. British Journal of Cancer 2001; 85: 997-1005.
  4. Demir C, Atmaca M, Tasdemir E, Efe S. Association of multiple myeloma and gastric adenocarcinoma. Journal of Clinical and Experimental Investigations 2011; 2: 110-3.
  5. Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer Journal, 2013; 3: e121. Kyle RA. Long-term survival in multiple myeloma. N Engl J Med, 1983; 308: 314-6.
  6. Spedini P, Marchetti G, Morandi S. Gastric localization of multiple myeloma. Haematologica, 2001; 86: 223. Grudeva-Popova J, Nenova I, Spasova M, Yaneva M, Beleva E, ?nanoshtev N. Multiple myeloma in association with second malignancy. JBUON 2013; 18: 448-52.
  7. Cui Y, Liu T, Zhou Y, Ji Y, Hou Y, Jin W, et al. Five Cases Report of Solid Tumor Synchronously with Hematologic Malignancy. Cancer Res Treat, 2012; 44: 63-8.